Table 1 Selected significant canonical pathways altered from induction of BRN2 expression.
From: BRN2 expression increases anoikis resistance in melanoma
Canonical pathway | -log (p value) | Ratio | Molecules |
|---|---|---|---|
ILK signaling | 4.53 | 0.09 | ACTA2, FERMT2, FOS, IRS2, ITGB1, NFKB1, PDGFC, PIK3C3, PPP2CA, PPP2R5A, PPP2R5E, PTGS2, RND3, TMSB10/TMSB4X, VCL, VEGFC |
PDGF signaling | 4.09 | 0.12 | EIF2AK2, FOS, PDGFC, PDGFD, PIK3C3, RALA, RRAS, STAT1, STAT3, SYNJ1 |
PI3K/AKT signaling | 3.81 | 0.09 | CDKN1A, FOXO1, ITGA4, ITGB1, NFKB1, PPP2CA, PPP2R5A, PPP2R5E, PTGS2, RALA, RRAS, SYNJ1 |
JAK/Stat signaling | 3.63 | 0.11 | CDKN1A, FOS, NFKB1, PIK3C3, RALA, RRAS, STAT1, STAT2, STAT3 |
IGF-1 signaling | 3.41 | 0.10 | CCN1, CCN2, FOS, FOXO1, IRS2, PIK3C3, PRKACB, RALA, RRAS, STAT3 |
CDK5 signaling | 3.31 | 0.09 | BDNF, EGR1, FOSB, ITGB1, PPP2CA, PPP2R5A, PPP2R5E, PRKACB, RALA, RRAS |
ERK/MAPK signaling | 3.29 | 0.07 | FOS, ITGA4, ITGB1, PIK3C3, PLA2G4A, PPARG, PPP2CA, PPP2R5A, PPP2R5E, PRKACB, RALA, RRAS, STAT1, STAT3 |
HGF signaling | 3.21 | 0.09 | CDKN1A, FOS, ITGA4, ITGB1, MET, PIK3C3, PTGS2, RALA, RRAS, STAT3 |
PAK signaling | 3.04 | 0.09 | ITGA4, ITGB1, MYL12B, PDGFC, PDGFD, PIK3C3, RALA, RRAS, WASL |
PPAR signaling | 2.30 | 0.08 | FOS, NFKB1, PDGFC, PDGFD, PPARG, PTGS2, RALA, RRAS |
PTEN signaling | 2.23 | 0.07 | CDKN1A, FOXO1, ITGA4, ITGB1, NFKB1, RALA, RRAS, SYNJ1, TGFBR2 |
mTOR signaling | 2.19 | 0.06 | EIF4G3, NAPEPLD, PDGFC, PIK3C3, PPP2CA, PPP2R5A, PPP2R5E, RALA, RND3, RPS6KA3, RRAS, VEGFC |
Integrin signaling | 2.11 | 0.06 | ACTA2, ARPC5, ITGA4, ITGAV, ITGB1, MYL12B, PIK3C3, RALA, RND3, RRAS, VCL, WASL |
AMPK signaling | 2.03 | 0.06 | AK3, CDKN1A, FOXO1, IRS2, PIK3C3, PPM1B, PPM1D, PPM1E, PPP2CA, PPP2R5A, PPP2R5E, PRKACB |
FAK signaling | 1.94 | 0.07 | ACTA2, ITGA4, ITGB1, PIK3C3, RALA, RRAS, VCL |
